$DARE
Dare Bioscience, Inc.

2021 Q4 Form 10-Q Financial Statement

#000140191421000137 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.427M $2.236M $1.823M
YoY Change 34.81% 62.05% 15.36%
% of Gross Profit
Research & Development $7.116M $10.43M $7.340M
YoY Change 7.18% 68.17% 32.32%
% of Gross Profit
Depreciation & Amortization $7.040K $6.350K $3.020K
YoY Change -68.25% -69.8%
% of Gross Profit
Operating Expenses $9.543M $12.67M $9.163M
YoY Change 13.07% 67.1% 28.59%
Operating Profit -$12.67M -$9.163M
YoY Change 67.1% 28.59%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $830.00 $1.508K $175.00
YoY Change -252.94% -89.18%
Pretax Income -$9.542M -$12.67M -$9.163M
YoY Change 13.06% 67.12% 28.69%
Income Tax
% Of Pretax Income
Net Earnings -$9.542M -$12.67M -$9.163M
YoY Change 13.06% 67.05% 28.61%
Net Earnings / Revenue
Basic Earnings Per Share -$0.18 -$0.18
Diluted Earnings Per Share -$183.4K -$0.18 -$0.18
COMMON SHARES
Basic Shares Outstanding 76.60M shares 70.78M shares 50.44M shares
Diluted Shares Outstanding 70.78M shares 50.44M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.67M $45.57M $9.112M
YoY Change 1006.51% 745.47% 70.31%
Cash & Equivalents $51.67M $45.57M $9.112M
Short-Term Investments
Other Short-Term Assets $2.477M $2.516M $1.992M
YoY Change 33.87% 82.33% -11.46%
Inventory
Prepaid Expenses $2.477M $2.516M $1.992M
Receivables
Other Receivables $1.145M $156.2K $2.955M
Total Short-Term Assets $55.30M $48.24M $14.06M
YoY Change 691.76% 590.72% 80.78%
LONG-TERM ASSETS
Property, Plant & Equipment $26.04K $33.09K $24.91K
YoY Change -31.34% -21.87% -54.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $485.1K $535.2K $738.3K
YoY Change -8.27% -15.71% -0.05%
Total Long-Term Assets $511.2K $568.3K $763.2K
YoY Change -9.82% -16.09% -3.82%
TOTAL ASSETS
Total Short-Term Assets $55.30M $48.24M $14.06M
Total Long-Term Assets $511.2K $568.3K $763.2K
Total Assets $55.81M $48.81M $14.82M
YoY Change 639.1% 537.08% 72.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.103M $605.7K $216.0K
YoY Change 105.92% -61.05% -87.4%
Accrued Expenses $3.136M $3.777M $4.370M
YoY Change -6.65% 53.9% 166.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.05M $15.91M $6.005M
YoY Change 109.55% 99.72% -1.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $1.016M $1.074M
YoY Change -100.0% -5.94% -50.76%
Total Long-Term Liabilities $0.00 $1.016M $1.074M
YoY Change -100.0% -5.94% -50.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.05M $15.91M $6.005M
Total Long-Term Liabilities $0.00 $1.016M $1.074M
Total Liabilities $17.05M $16.92M $7.078M
YoY Change 95.95% 87.04% -14.3%
SHAREHOLDERS EQUITY
Retained Earnings -$110.1M -$100.6M -$87.90M
YoY Change 54.17% 59.68% 58.66%
Common Stock $149.0M $132.6M $145.8M
YoY Change 111.79% 114.92% 161.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.75M $31.89M $7.744M
YoY Change
Total Liabilities & Shareholders Equity $55.81M $48.81M $14.82M
YoY Change 639.1% 537.08% 72.95%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$9.542M -$12.67M -$9.163M
YoY Change 13.06% 67.05% 28.61%
Depreciation, Depletion And Amortization $7.040K $6.350K $3.020K
YoY Change -68.25% -69.8%
Cash From Operating Activities -$9.916M $1.320M -$11.79M
YoY Change 7.9% -124.63% 188.93%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$14.52K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$14.52K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $36.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.00M 35.22M 13.26M
YoY Change 89.39% 552.16% 201.97%
NET CHANGE
Cash From Operating Activities -9.916M 1.320M -11.79M
Cash From Investing Activities 0.000 -14.52K 0.000
Cash From Financing Activities 16.00M 35.22M 13.26M
Net Change In Cash 6.088M 36.52M 1.468M
YoY Change -922.69% 91205.82% 406.2%
FREE CASH FLOW
Cash From Operating Activities -$9.916M $1.320M -$11.79M
Capital Expenditures $0.00 -$14.52K $0.00
Free Cash Flow -$9.916M $1.335M -$11.79M
YoY Change 7.9% -124.9% 190.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001401914
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
dei Document Type
DocumentType
10-Q
dei Entity Small Business
EntitySmallBusiness
true
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
DARÉ BIOSCIENCE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity File Number
EntityFileNumber
001-36395
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4139823
dei Entity Address Address Line1
EntityAddressAddressLine1
3655 Nobel Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 260
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
926-7655
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
DARE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
605732 USD
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76601624 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45570781 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4669467 USD
CY2021Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
156247 USD
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
460168 USD
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2516126 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1854277 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
48243154 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
6983912 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33088 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37930 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
535234 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
528870 USD
CY2021Q3 us-gaap Assets
Assets
48811476 USD
CY2020Q4 us-gaap Assets
Assets
7550712 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1021333 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3776744 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3359718 USD
CY2021Q3 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
11156599 USD
CY2020Q4 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
1564553 USD
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
367285 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1000000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
368011 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
347712 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15907086 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7660601 USD
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1000000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1000000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15799 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41844 USD
CY2021Q3 us-gaap Liabilities
Liabilities
16922885 USD
CY2020Q4 us-gaap Liabilities
Liabilities
8702445 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76601624 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76601624 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41596253 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41596253 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
7660 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
4159 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-170390 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-91388 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
132635942 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
70366293 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100584621 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71430797 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
31888591 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-1151733 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48811476 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7550712 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2211334 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1353069 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5949299 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4772382 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10432603 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6203753 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23501098 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14131007 USD
CY2021Q3 dare License Fee
LicenseFee
25000 USD
CY2020Q3 dare License Fee
LicenseFee
25000 USD
dare License Fee
LicenseFee
75000 USD
dare License Fee
LicenseFee
58333 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
12668937 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
7581822 USD
us-gaap Operating Expenses
OperatingExpenses
29525397 USD
us-gaap Operating Expenses
OperatingExpenses
18961722 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12668937 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7581822 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-29525397 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-18961722 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1508 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-986 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1686 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2454 USD
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
369887 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12667429 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7588999 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7582808 USD
us-gaap Net Income Loss
NetIncomeLoss
-29153824 USD
us-gaap Net Income Loss
NetIncomeLoss
-18959268 USD
CY2021Q3 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
0 USD
CY2020Q3 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
6863 USD
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
0 USD
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
6863 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12667429 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7589671 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29153824 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18966131 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-63281 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
672 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-79002 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-10182 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12730710 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29232826 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18976313 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70775508 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70775508 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31588152 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31588152 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64196162 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64196162 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27381508 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27381508 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-1151733 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
365911 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11324140 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
50400 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7323644 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6841 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
3258233 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
405478 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13251924 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9162751 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8880 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
7744004 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
439497 USD
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
35012048 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
204466 USD
CY2021Q3 dare Stock Issued During Period Value Milestone Payment
StockIssuedDuringPeriodValueMilestonePayment
1219286 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12667429 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-63281 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
31888591 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
440826 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
160841 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5222687 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1665020 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4252248 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-22944 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
3214183 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
186859 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4022336 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7124213 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12090 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
311255 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
194882 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5277622 USD
CY2020Q3 dare Stock Issued During Period Value Consideration For Commitment To Purchase Shares
StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares
291529 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
120960 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7582808 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
672 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-1385888 USD
us-gaap Net Income Loss
NetIncomeLoss
-29153824 USD
us-gaap Net Income Loss
NetIncomeLoss
-18959268 USD
us-gaap Depreciation
Depreciation
19366 USD
us-gaap Depreciation
Depreciation
36428 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1210886 USD
us-gaap Share Based Compensation
ShareBasedCompensation
542582 USD
dare Non Cash Lease Expense
NonCashLeaseExpense
-69356 USD
dare Non Cash Lease Expense
NonCashLeaseExpense
-125517 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
44286 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
369887 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-303921 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-341650 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
661849 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-18682 USD
dare Increase Decrease In Other Non Current Assets And Deferred Charges
IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
-57247 USD
dare Increase Decrease In Other Non Current Assets And Deferred Charges
IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
-118044 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-415602 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
472124 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
594629 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
355395 USD
dare Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
-9592045 USD
dare Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
-158704 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18848138 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16041176 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14524 USD
dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
1785980 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15246 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14524 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15246 USD
dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
59588112 USD
dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
14522645 USD
dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
254866 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
367285 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59842978 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16675911 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-79002 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-10182 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
40901314 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
609307 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4669467 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4780107 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45570781 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5389414 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
308533 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
dare Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability
NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability
925000 USD
dare Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability
NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability
0 USD
dare Milestone Payments Contingent Amount
MilestonePaymentsContingentAmount
250000 USD
dare Milestone Payments Contingent Amount
MilestonePaymentsContingentAmount
0 USD
dare Issuance Cost On Equity Paid In Common Stock
IssuanceCostOnEquityPaidInCommonStock
0 USD
dare Issuance Cost On Equity Paid In Common Stock
IssuanceCostOnEquityPaidInCommonStock
291428 USD
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
0 USD
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
6863 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100600000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45600000 USD
CY2021Q3 dare Working Capital Increase Deficit
WorkingCapitalIncreaseDeficit
32300000 USD
us-gaap Net Income Loss
NetIncomeLoss
-29200000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
18800000 USD
dare Periodof Insufficient Cashand Liquidity Requirements
PeriodofInsufficientCashandLiquidityRequirements
P12M
CY2021Q3 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
4159122 USD
dare Weighted Average Amortization Period
WeightedAverageAmortizationPeriod
P2Y11M1D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0097
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0066
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.22
CY2021Q3 dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.000
dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.02
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
50000000 USD
CY2021Q2 dare Percentage Of Aggregate Commission
PercentageOfAggregateCommission
0.03
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
18300000 shares
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
36200000 USD
CY2021Q3 dare Offering Expenses
OfferingExpenses
1200000 USD
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
26000000 shares
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46900000 USD
dare Offering Expenses
OfferingExpenses
1600000 USD
CY2018Q1 dare Percentage Of Aggregate Commission
PercentageOfAggregateCommission
0.030
CY2021Q3 dare Deferred Offering Costs Unamortized Portion
DeferredOfferingCostsUnamortizedPortion
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
207000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.00
CY2019Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.98
CY2020Q3 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.96
CY2019Q2 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
800000 USD
CY2020Q3 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
6863 USD
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
265485 shares
dare Gross Proceeds From Warrants Exercised
GrossProceedsFromWarrantsExercised
255000 USD
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1825000 shares
dare Gross Proceeds From Warrants Exercised
GrossProceedsFromWarrantsExercised
1800000 USD
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1643158 shares
CY2018Q3 us-gaap Net Rentable Area
NetRentableArea
3169 sqft
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2018Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.07
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
368000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16000 USD
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
134000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
76000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
420000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
228000 USD
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
117000 USD
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
111000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
343000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
349000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M21D
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
119000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
278000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
397000 USD
CY2021Q1 dare Notes Payable Current Plus Accrued Interest
NotesPayableCurrentPlusAccruedInterest
369887 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
384000 USD
dare Payment Of Additional Consideration In Business Combination
PaymentOfAdditionalConsiderationInBusinessCombination
46500000 USD
CY2020Q2 dare Coronavirus Aid Reliefand Economic Security Act Loan Proceeds Received
CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived
367285 USD
CY2018 dare Proceeds From Award Of Grant
ProceedsFromAwardOfGrant
1900000 USD
CY2020Q2 dare Proceeds From Award Of Grant
ProceedsFromAwardOfGrant
731000 USD
CY2021Q3 dare Proceeds From Award Of Grant
ProceedsFromAwardOfGrant
11450000 USD
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6445824 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4692234 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6445824 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4692234 shares

Files In Submission

Name View Source Status
0001401914-21-000137-index-headers.html Edgar Link pending
0001401914-21-000137-index.html Edgar Link pending
0001401914-21-000137.txt Edgar Link pending
0001401914-21-000137-xbrl.zip Edgar Link pending
dare-20210930.htm Edgar Link pending
dare-20210930.xsd Edgar Link pending
dare-20210930_cal.xml Edgar Link unprocessable
dare-20210930_def.xml Edgar Link unprocessable
dare-20210930_g1.jpg Edgar Link pending
dare-20210930_htm.xml Edgar Link completed
dare-20210930_lab.xml Edgar Link unprocessable
dare-20210930_pre.xml Edgar Link unprocessable
ex101.htm Edgar Link pending
ex102.htm Edgar Link pending
exhibit311_20210930.htm Edgar Link pending
exhibit312_20210930.htm Edgar Link pending
exhibit321_20210930.htm Edgar Link pending
exhibit322_20210930.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_0a.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending